Skip to content

G&A at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$12.47M+69.9%
Vor Biopharma logo
Vor BiopharmaVOR
$17.57M+167%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$11.57M-14.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$13.44M-44.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$26.2M+85.4%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$7.39M+120%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's G&A?
Annexon (ANNX) reported G&A of $10.27M in Q1 2026.
How has Annexon's G&A changed year-over-year?
Annexon's G&A increased by 11.3% year-over-year, from $9.23M to $10.27M.
What is the long-term trend for Annexon's G&A?
Over 4 years (2021 to 2025), Annexon's G&A has grown at a 0.9% compound annual growth rate (CAGR), from $30.65M to $31.71M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.